Villejuif Cedex, France - Transdermal delivery of estrogen does not appear to be associated with the same risk of venous thromboembolism as that seen with oral estrogen, a new meta-analysis suggests ...

Please provide your email address to receive an email when new articles are posted on . Reducing the dosage of progesterone in postmenopausal women on low-dose transdermal hormone therapies provided ...

Bethesda, MD - In a head-to-head crossover comparison, oral estrogen therapy (ET) was associated with a sustained increase in the inflammatory marker C-reactive protein (CRP) among postmenopausal ...

Based on phase 3 trial findings, investigators conclude that transdermal estradiol should be a standard of care ADT option for patients with nonmetastatic prostate cancer. Transdermal estradiol (tE2) ...

CLEVELAND, Ohio (October 11, 2017)--Did you know you're two-to-four-times more likely to suffer from depression during the menopause transition? A new study suggests that transdermal estradiol could ...

Postmenopausal women on transdermal HT experienced a lower incidence of anxiety and depression compared with those receiving oral HT. HealthDay News — For postmenopausal women, transdermal hormone ...

New Haven, CT - April 19, 2004 – Low-dose transdermal hormone therapy (HT) remains a viable short-term alternative for women to treat debilitating menopausal symptoms, offer lipid protection and ...

The proportion of patients achieving a prostate-specific antigen nadir less than or equal to 0.2 ng/ml was exactly the same for patients treated with transdermal estradiol patches and those treated ...

Estradiol 0.05mg/day, 0.1mg/day; ext-rel transdermal film. Initially one 0.05mg/day patch twice per week applied to trunk (avoid breasts, waistline). May be given continuously if patient does not have ...

Transdermal estrogen therapy delivered through the skin modestly improved sexual function in early postmenopausal women, according to an article. Transdermal estrogen therapy delivered through the ...

MIAMI, Fla. & NEW YORK -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has acquired commercialrights to Minivelle™ (estradiol ...